This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Imagine a future in which a patient walks into an eye clinic with burning, light-stung eyes and an exam that looks almost normal. The doctor does not offer sympathy and a list of things already tried. She writes a prescription for a medicine approved for exactly this. That scene is not possible today. In the words of Dr. Melissa Toyos of the Toyos Clinic in Nashville, there is currently “no FDA approved therapy to offer these patients.” This week a drug developer took the step that makes the scene at least thinkable.

The company is OKYO Pharma Limited (Nasdaq: OKYO). It describes itself as a clinical-stage biopharmaceutical company, headquartered in London, that is developing investigational therapies for neuropathic corneal pain and other diseases of the front of the eye. Its ordinary shares trade on the Nasdaq Capital Market.

What happened

On October 6, 2026, OKYO Pharma said the first patients had been enrolled in NEPTUNE, its Phase 3 trial of urcosimod for neuropathic corneal pain. According to the announcement, Dr. Toyos enrolled them at the Toyos Clinic in Nashville, Tennessee. The company said other sites are being activated across leading U.S. medical centers, and that patients will be enrolled at sites in the United States and Europe, including Italy, Spain and France. Patients receive four drops a day for 12 weeks. The primary measure is the change in ocular pain on a visual analogue scale, a standard patient-rated pain score. Additional measures include quality-of-life scores and in-vivo confocal microscopy, an imaging method that lets doctors look at the corneal nerves themselves. The company said the trial is designed as a registrational study “in accordance with” FDA guidance. In plain terms, it is meant to produce evidence that could support an approval application. The announcement does not say the trial will succeed, and it gives no timeline for results.

The thread

Put the pieces together and OKYO’s focus is clear: a lead drug aimed at a condition that, by the company’s account, has no FDA-approved treatment. The company describes neuropathic corneal pain as a chronic and often severe condition. It is thought to stem from damaged or malfunctioning corneal nerves, often alongside inflammation, and the pain can be out of proportion to anything a doctor can see. That mismatch helps explain why the condition is hard to treat and hard to study.

Urcosimod is OKYO’s lead candidate, and the company describes it as first-in-class. It is a lipid-conjugated peptide that activates a receptor called ChemR23. According to the company, that receptor sits on immune cells in the eye that drive inflammation and also on nerve and support cells in the dorsal root ganglion, a cluster of sensory nerve cells. OKYO says the drug has shown both pain-relieving and anti-inflammatory activity through this dual mechanism. The pitch, as this desk reads it, is a single molecule that calms the fire and quiets the alarm at the same time.

Before this week, that was an idea under investigation. Now it is an idea being tested in a trial built to support a regulatory filing. For OKYO, that is the difference between a research program and a potential product.

Three roads from here

The good road. NEPTUNE could enroll steadily across its American and European sites, and the pain scores could show clear improvement. If the confocal microscopy images also show changes in the corneal nerves, OKYO’s chief medical officer, Flavio Mantelli, would have support for his description of urcosimod as a potential first disease-modifying treatment. In that version, OKYO might become the company that defined a treatment category from scratch.

The dull road. The trial could run, and run, and run. Conditions defined by patient-reported pain are notoriously vulnerable to placebo response, and patients who have “tried everything” can be hard to find and keep. A slow, muddy readout might leave urcosimod looking promising but unproven, which is an uncomfortable place for a company whose lead candidate it is.

The difficult road. The pain endpoint could miss. A first-in-class mechanism carries first-in-class uncertainty, and nothing in this announcement guarantees that what the company calls demonstrated pharmacologic activity becomes a clinically meaningful benefit in a large trial. If that happened, OKYO would face hard questions about its future with no second product named in these documents to fall back on.

The signpost is the pace of site activation, followed by any disclosure about enrollment progress. A company that announces site after site across Italy, Spain and France is on the first road or the second. A company that goes quiet is telling readers something too.

The desk’s view

To our eye, this is a genuine milestone. Starting a registrational trial in a condition with no approved therapy is a meaningful step. We also like the trial design. Pairing a subjective pain score with objective nerve imaging is a sensible way to answer the obvious skeptic’s question: is anything actually changing in the eye?

What we would ask about is the language. “Registrational” and “first disease modifying” are ambitions written into a press release, and the release itself measures success primarily by pain, not by nerve repair. The announcement says the design follows FDA guidance. It does not say the agency has signed off on the protocol, and readers should not assume it has. We would also note that the filing is incorporated by reference into OKYO’s registration statement on Form F-3, and the documents say nothing about how the trial is funded. A first patient is a beginning. Whether it turns into a breakthrough, or not, depends on many decisions this announcement does not settle.

What to watch

The company gave no dates for enrollment completion or for results. The named next steps are activation of further sites across leading U.S. medical centers and enrollment at sites in Italy, Spain and France. Details of the study are registered on clinicaltrials.gov under NCT07838506. For now, the scene in that imagined clinic is no longer pure fiction. It is a trial, and it has just begun.

Sources